Alector, Inc. (ALEC)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC). Investors who purchased Alector securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Alector has violated federal securities laws.
Investigation Details
On October 21, 2025, Alector issued a press release “announcing results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).” According to the Company, its drug candidate “did not meet the clinical co-primary endpoint of slowing FTD-GRN progression,” and “the secondary and exploratory endpoints, such as fluid biomarkers and volumetric magnetic resonance imaging (vMRI), demonstrated no treatment-related effects on FTD-GRN.” Following this news, Alector’s stock price dropped almost 50% the next day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Alector securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]